Three Promising ARVs of the Next Generation
Dolutegravir, Compnay:ViiV ,Action:Approved ,Very high barrier to resistance and better regimen durability,Reduced manufacturing cost,
Reduced side effects compared with efavirenz,Potential for first- or second-line treatment,More rapid decrease in viral load may increase efficacy for prevention of mother-to-child transmission among women initiating ART late in gestation,Low dosage convenient for pediatric formulations,May not reduce efficacy of progestin-containing contraceptive implants, which is a possible concern with efavirenz.
TAF Company:Gilead,Action :Late Phase III,Lower risk of renal and bone toxicity than TDF,Lower manufacturing cost than TDF,Potential for first- or second-line treatment, with possible greater efficacy than TDF for viruses resistant to some nucleosides/nucleotides.
Doravirine,Company:Merck,Action:Early Phase III,Lower rates of central nervous system adverse events than efavirenz reported in phase II studies,Possible low manufacturing cost given low dose,May have better activity against many non-nucleoside reverse transcriptase resistant isolates common in sub-Saharan Africa, leading to possible utility in second-line combinations.Characteristics (lack of food requirement, shorter half-life, lower potential for TB medication interactions) might make it a better partner for dolutegravir than rilpivirine as part of a simplified, low-cost 2-drug maintenance regimen.
Abbreviations: ART, antiretroviral therapy; ARV,HAART,AIDS/HIV TREATING MODERN MEDICINE APRROVED BY FDC & NACO,WHO